Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 10(1): 3271, 2020 02 24.
Article in English | MEDLINE | ID: mdl-32094351

ABSTRACT

Gastric carcinoma (GC) locoregional recurrence may occur even in cases where the tumor has been completely resected, possibly due to lymph node (LN) micrometastases. It is estimated that in 10% to 30% of cases, LN micrometastases are not detected by a conventional method for histological assessment of LN metastases with hematoxylin-eosin (HE). A cross-sectional study assessed 51 patients with GC by histological evaluation of the LN micrometastases through LN multi sectioning associated with immunohistochemistry analysis with monoclonal antibodies AE1 and AE3. Total gastrectomy was performed in 51% of patients. The total number of resected LN nodes was 1698, with a mean number of resected LN of 33.3 ± 13.2 per surgical specimen, of which 187 had metastasis. After the application of LN multisection and immunohistochemistry, LN micrometastases were found in 45.1% of the cases. LN staging changed in 29.4%, and tumor staging changed in 23.5% of the cases. In patients initially staged as pN0, LN staging and tumor staging changed, both in 19.2% of the cases. In patients initially staged as pN1 or more, LN staging changed in 40.0% of them, and tumor staging changed in 28.0% of the cases. The accuracy of HE for the histological staging of LN tumoral involvement was 76%, which was considered insufficient for CG patients staging. Investigation of LN micrometastasis through LN multisection and immunohistochemistry should be performed, particularly in cases where the presence of blood and lymphatic vessel invasion has been identified after conventional histological analysis, as well as in patients with advanced GC.


Subject(s)
Carcinoma/diagnosis , Lymph Nodes/pathology , Neoplasm Recurrence, Local/diagnosis , Stomach Neoplasms/diagnosis , Aged , Carcinoma/pathology , Cross-Sectional Studies , Female , Gastrectomy , Humans , Immunohistochemistry , Lymphatic Metastasis/pathology , Male , Middle Aged , Neoplasm Metastasis , Neoplasm Micrometastasis/pathology , Neoplasm Recurrence, Local/pathology , Neoplasm Staging , Reproducibility of Results , Stomach Neoplasms/pathology
2.
Thyroid ; 17(11): 1055-9, 2007 Nov.
Article in English | MEDLINE | ID: mdl-18047428

ABSTRACT

CONTEXT: Chromosomal fragile sites are often related to cancer development. The WW domain-containing oxidoreductase gene (WWOX) spans the second most common chromosomal fragile site (FRA16D) and encodes an important proapoptotic protein. OBJECTIVE: To verify our hypothesis that underexpression of WWOX could contribute to malignant transformation of the thyroid cells. METHOD: We compared WWOX expression among follicular adenomas (FAs) and differentiated thyroid carcinomas [follicular thyroid carcinomas (FTCs) and papillary thyroid carcinomas (PTCs)] in 53 thyroid tumors resected from patients submitted to total thyroidectomy. DESIGN: Multiple fields of tumor areas of FAs, FTCs, and PTCs as well as normal thyroid tissue were stained with WWOX antiserum, and classified by the extent of staining (percentage of cells staining) and staining intensity. MAIN OUTCOME: PTCs showed a significantly decreased expression of WWOX when compared to FAs and FTCs. Further, using a unique model of comparison in patients in whom FAs and PTCs were concomitantly present, we detected the same result (i.e., no expression in PTCs). CONCLUSION: We conclude that WWOX underexpression is an important step that might increase the vulnerability to the carcinogenesis process in PTCs.


Subject(s)
Oxidoreductases/biosynthesis , Thyroid Neoplasms/etiology , Tumor Suppressor Proteins/biosynthesis , Adenocarcinoma, Follicular/metabolism , Carcinoma, Papillary/metabolism , Cell Transformation, Neoplastic/metabolism , Chromosome Fragile Sites/physiology , Humans , Thyroid Neoplasms/physiopathology , WW Domain-Containing Oxidoreductase
SELECTION OF CITATIONS
SEARCH DETAIL
...